Form 8-K - Current report:
SEC Accession No. 0001140361-24-044317
Filing Date
2024-10-28
Accepted
2024-10-25 20:49:15
Documents
16
Period of Report
2024-10-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20037731_8k.htm   iXBRL 8-K 44507
2 EXHIBIT 10.1 ef20037731_ex10-1.htm EX-10.1 98078
3 EXHIBIT 10.2 ef20037731_ex10-2.htm EX-10.2 193575
4 EXHIBIT 99.1 ef20037731_ex99-1.htm EX-99.1 14893
  Complete submission text file 0001140361-24-044317.txt   561678

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20241024.xsd EX-101.SCH 3979
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20241024_lab.xml EX-101.LAB 21966
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20241024_pre.xml EX-101.PRE 16042
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20037731_8k_htm.xml XML 4227
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 241398223
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)